Literature DB >> 10498158

Status of treatment of depression.

K E Broquet1.   

Abstract

BACKGROUND: Depression is a common and highly treatable disorder, with most patients returning to predepression levels of functioning. Patients with depression must be carefully assessed for the presence of comorbid psychiatric or medical disorders, as well as psychosocial stresses.
METHODS: I present a clinical overview, supported by pertinent literature, of currently available treatments of depression, with an emphasis on primary practice.
RESULTS: Beyond diagnosis, treatment consists of patient education and support, evaluation of suicide risk, and treatment of symptoms with antidepressant medication, psychotherapy, or both. A multitude of antidepressants are available, including cyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs), monoamine oxidase inhibitors (MAOIs), and newer, more receptor-specific agents such as nefazodone, venlafaxine, and mirtazapine. These are reviewed with a focus on mechanism of action, side-effect profile, and clinical use.
CONCLUSIONS: All available antidepressants have been found effective in the treatment of mild-to-moderate depression. Choice of agent is based primarily on side-effect profile. For patients with an atypical pattern of symptoms, SSRIs or MAOIs may be the most useful. Patients with severe depression or melancholic symptoms may respond better to tricyclic antidepressants, venlafaxine, or mirtazapine.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10498158

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  5 in total

Review 1.  Venlafaxine extended-release: a review of its use in the management of major depression.

Authors:  K Wellington; C M Perry
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 2.  Escitalopram : a review of its use in the management of major depressive and anxiety disorders.

Authors:  John Waugh; Karen L Goa
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 3.  Paroxetine: an update of its use in psychiatric disorders in adults.

Authors:  Antona J Wagstaff; Susan M Cheer; Anna J Matheson; Douglas Ormrod; Karen L Goa
Journal:  Drugs       Date:  2002       Impact factor: 9.546

4.  Trimipraminium maleate.

Authors:  Jerry P Jasinski; Ray J Butcher; Q N M Hakim Al-Arique; H S Yathirajan; B Narayana
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2010-01-16

5.  Chitosan Spray-Dried Microparticles for Controlled Delivery of Venlafaxine Hydrochloride.

Authors:  Inmaculada Aranaz; Ines Paños; Carlos Peniche; Ángeles Heras; Niuris Acosta
Journal:  Molecules       Date:  2017-11-15       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.